Dermatology III Flashcards
List 4 malignant neoplasms
1) Basal Cell Carcinoma (BCC)
2) Squamous Cell Carcinoma (SCC)
3) Melanoma
4) Kaposi Sarcoma
1) What is the most common cancer?
2) Demographic, age of onset, & etiology?
3) Where does it most commonly occur?
1) BCC
2) Onset >40 y/o, M>F, ultraviolet light (UVB)
3) In fair-skin (I-III) rare in brown & black skin (V-VI,) 70% on face/chest. “Danger sites”: medial/lateral canthi, nasolabial fold, post-auricular
Basal cell carcinoma (BCC):
1) List risk factors
2) Describe the Sx and speed of progression
1) Fair skin (I-III), albinos, light-colored eyes, red hair, prolonged sun exposure, northern European ancestry, older age, heavy sun exposure in youth, tanning beds
2) Slow growing, usually asymptomatic, but can bleed/scab or feel sensitive if on a nerve
What are the clinical & histologic sub-types of BCC?
1) Clinical: superficial, nodular, pigmented, morpheaform
2) Histologic: superficial, nodular, micronodular, infiltrative
Basal cell carcinoma (BCC):
1) DDxs?
2) How is it diagnosed?
3) Txs?
1) All smooth papules, melanoma, all non-painful ulcers (SCC, syphilis)
2) Clinical, confirmed microscopically with biopsy
3) Excision with primary closure
-Cryosurgery & electrosurgery (limited)
-Mohs is best for morpheaform & lesions in danger or cosmetically sensitive sites and scalp
-Topical (5-fluorouracil ointment & imiquimod) for superficial lesions below neck
-Treatment depends on location, size and type
1) What is the most common subtype of BCC?
2) What does it look like?
1) Skin-colored or reddish, translucent (“pearly”), well-defined, firm, smooth papule or nodule with telangiectasia
2) Erosions & melanin stipples; Ulceration with crust & rolled border
Pigmented BCC:
1) What colors can it be?
2) What does it feel/ look like?
3) DDxs?
1) Brown, blue, or black
2) Hard, firm; Round, oval, can be ulcerated
3) Superficial spreading melanoma, nodular melanoma
Morpheaform BCC:
1) What is this form also called? What % of BCC cases?
2) What does it look like?
1) Sclerosing BCC; 5-10% of BCC cases
2) Smooth, flesh-colored or light erythematous papules or plaques, atrophic. ill-defined borders.
-Scar-like appearance in some areas
Squamous cell carcinoma (SCC):
1) Demographic/ age of onset?
2) Risk factors?
3) What types of lesions can it present as?
1) >55 y/o, M>F
2) Sun exposure, light-colored skin, easily burns/poor tanning, outdoor occupations-pilots/truckers/farmers, immunosuppression (organ transplant, HIV,) chronic inflammation, industrial carcinogens
3) Solitary or multiple macules, papules, plaques, ulcers
SCC:
1) Is it always smooth?
2) What may it arise from?
3) Does it progress quickly?
4) How is it diagnosed?
1) Hyperkeratotic or scaling
2) May arise from AK
3) Can rapidly evolve
4) Biopsy (shave, punch, or excisional)
Squamous cell carcinoma (SCC)
1) How is it treated in situ?
2) What about invasively?
1) Imiquimod or 5-fluorouracil, curettage & electrodessication
2) Excision or Mohs surgery
Superficial SCC
1) What is the most common site?
2) How does it typically present?
3) What is a DDx?
1) Most common site = trunk
2) Slightly scaly, macules, patches, or thin plaques light red to pink in color. Telangectasias may be seen.
3) Actinic keratosis (AK)
Why is MMS the preferred method?
Offers superior histologic analysis of tumor margins while permitting maximal conservation of tissue compared with standard surgical excision
-Recurrence rates tend to be lower with MMS compared to other modalities, including standard electro-desiccation and curettage, radiation, and cryotherapy
What are some indications for Mohs Micrographic surgery (MMS)?
1) Lesions on nose, ears, eyes, lips, scalp, hands, and cosmetically sensitive areas
2) Aggressive histologic subtypes: infiltrative, sclerosing, morpheaform, or micronodular
3) Large tumors or tumors with indistinct clinical borders
4) Recurrent tumors
What is the leading cause of death due to skin disease and least common type of skin cancer?
Melanoma
1) What is the most common malignant tumor of the skin?
2) Demographic?
3) Etiology/ pathogenesis?
1) Melanoma
2) 1 in 4 cases before age 40
3) Lifetime risk 2% Caucasians, 0.1-0.5% non- Caucasian
Etiology & pathogenesis unknown (likely due to exposure to solar radiation)
1) What is the single most important prognostic factor for melanomas?
2) Describe this
3) How many major clinicohistologic types are there?
1) Tumor thickness at time of Dx
2) 10-year survival related to thickness in mm
<1 mm = 95%,
1-2 mm = 80%
2-4 mm = 55%
3) Four
List the different presentations of melanoma (4 major clinicohistologic types) and how common they are
1) Superficial spreading 70%
2) Nodular 15%
3) Lentigo 5%
4) Acral lentiginous 5-10%
What is the single most important Hx reason for close eval and possible referral of a spot?
History of a changing mole (evolution, including bleeding & ulceration)
What is the mnemonic for clinical features of pigmented lesions suspicious for melanoma?
A: Asymmetry
B: Border irregularities (ill-defined)
C: Color variation (variegation)
D: Diameter > 6 mm
E: Evolution (changing in shape, size, color, or is new)
1) What are some DDxs for melanoma?
2) How is melanoma diagnosed?
1) Melanocytic lesions, non-melanocytic lesions, benign nevi
2) Clinical, ABCDE criteria, “ugly duckling” sign
Melanomas:
1) Describe how to Dx
2) Describe Tx options
1) Excisional biopsy-must take wide margin (1 cm margin for every 1mm of lesion depth.) vs punch biopsy
2) Excision & histology, followed by re-excision with borders based on thickness of tumor (pathology report)
-Referral to centers with expertise in melanomas for intermediate-to-high risk patients
-Sentinal lymph node biopsy: All lesions >1 mm thickness & high-risk histologic features (ulcers)
Kaposi sarcoma:
1) What is it? What is it linked with?
2) How does it present? How many variants are there and who are they seen in?
3) Tx?
1) Systemic endothelial cell tumor
Linked with HSV-8 infection
2) Purple, brown, black patches, plaques, & nodules
4 clinical variants (seen in those with immunodeficiencies/ HIV/AIDS)
3) Radiation, chemotherapy, antivirals- typically responds to treatment